Future in vivo studies with syngeneic mouse models are now needed to validate the efficacy of selective FKBP51 inhibitors in modulating tumour PD-L1 expression and, most importantly, to verify whether these small molecules are able to positively affect tumour microenvironment and ameliorate immune defences against glioma. This evidence concerns the gene CD274 and neoplasm.